Chronic end-organ complications result in morbidity and mortality in adults with sickle cell disease (SCD). In a retrospective-prospective cohort of 150 adults with SCD who received standard care screening for pulmonary function abnormalities, cardiac disease, and renal assessment from January
| INTRODUCTION
Sickle cell disease (SCD) is the most common inherited blood disorder, with almost 300 000 affected births annually and an estimated 100 000 affected individuals in the United States. 1 Fifty years ago, SCD was considered a pediatric disease because few affected children survived into adulthood. In contrast, > 98% of children with SCD born in high-income countries today are expected to reach adulthood. 2, 3 An aging population with SCD has led to an emerging burden of chronic SCD-associated end-organ complications. Complications such as stroke, chronic kidney disease, and cardiopulmonary disease contribute significantly to morbidity and early mortality in adults with SCD. 4 Irreversible end-organ damage such as pulmonary hypertension, end-stage renal disease, and cerebrovascular disease are associated with premature death. 4, 5 . Cardiopulmonary disease is the major, although not exclusive, cause of death in adults with SCD. [6] [7] [8] [9] Our group and others have previously demonstrated that in individuals with SCD, end-organ disease in the lung, heart, and kidney are typically related. Specifically, we demonstrated an association between elevated tricuspid regurgitant jet velocity (TRJV), a surrogate marker for pulmonary hypertension, and nephropathy in adults with SCD. 10 Others have identified an association between pulmonary hypertension and markers of renal injury, 5, 11, 12 cutaneous ulceration, 13 and priapism in males with SCD. 5 However, prior studies describing end-organ disease related mortality have tended to focus only on 1 organ (lung, heart, or kidney), without an emphasis on shared mechanisms and simultaneous involvement and progression of vasculopathy in multiple organs to multi-system end-organ damage. 14 Emerging evidence suggests that end-organ disease in the lungs, heart, and kidneys are likely to overlap and that chronic SCDassociated end-organ impairment contributes to morbidity and mortality in individuals with SCD. [6] [7] [8] 15 , 16 We tested the hypothesis that SCD-related chronic end-organ injury affecting multiple systems simultaneously is common, and that multiple-organ impairment is associated with early mortality in adults.
2 | METHODS
| Participants and data collection
The study population was drawn from a cohort of 182 adults with Equations. 17 We categorized FEV 1 % predicted values of ≤70% as end-organ lung disease because our group has shown that a threshold of ≤70% has been associated with a higher mortality rate in adults with SCA. 18 We defined a TRJV cutoff of ≥2.5 m/second as abnormally elevated and indicative of pulmonary hypertension based on the study by Gladwin et al. 5 and the American Thoracic Society clinical practice guideline on pulmonary hypertension in SCD. 19 Individuals with trace or no tricuspid regurgitation were classified as not having an elevated TRJV velocity. Nephropathy was defined as a serum creatinine of ≥2 mg/dL or 1.5 times the baseline creatinine (when this creatinine value is ≥1 mg/dL) or an estimated glomerular filtration rate of <60 mL/min/1.73 m 2 body surface area persistent over at least 3 months based on the National Kidney Foundation Kidney Disease
Outcomes Quality Initiative guidelines. 20 We followed the cohort prospectively for the development of organ impairment and the primary endpoint (death); however, we also collected any available retrospective data for organ function assessments conducted as standard care during the period before enrollment in the cohort.
We restricted the primary analyses to individuals that had at least 6 months of follow-up and had at least 1 measurement each for FEV 1 % predicted, TRJV, and serum creatinine and had no evidence of two or more end-organ disease at the time of enrollment. (N = 150).
Multiple end-organ disease was defined as more than 1 organ affected, including FEV 1 % predicted ≤ 70%, nephropathy, and elevated TRJV ≥ 2.5 m/second. Although we also attempt to perform annual magnetic resonance imaging with magnetic resonance angiography (MRI/MRA), adherence with this practice is low, and the same radiologist does not consistently interpret the images, which is important because previous studies have demonstrated significant interobserver variability when different radiologists interpret MRI scans for SCDspecific findings, such as silent cerebral ischemia. 21 Therefore, we excluded central nervous system findings from the analyses.
As per our routine clinical care, we screened for depression at every clinic visit using the Patient Health Questionnaire-9 (PHQ-9).
The PHQ-9 is a validated and reliable 9-item self-administered version of the Primary Care Evaluation of Mental Disorders diagnostic instrument to measure the presence and degree of, and to monitor for, depression, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day). 22 PHQ-9 score cutoffs of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression. We established a PHQ-9 score of ≥10 (which has a sensitivity and specificity of 88% each for major depression warranting treatment) 22 on 2 separate occasions at least 4 weeks apart as criterion for persistent depressive symptoms or depression.
We also collected information on disease-modifying therapies 3 | RESULTS
| Participant characteristics
Of 277 adults with SCD followed at the Vanderbilt-Meharry Center for Excellence in SCD, 182 are enrolled in the Tennessee Never Lost cohort. We excluded 11 individuals with less than 6 months follow-up and another 21 who had not completed at least 1 assessment of each organ (TRJV, FEV 1 % predicted, and serum creatinine) from the analysis. Therefore, the final analysis included 150 adults with a median follow-up period of 8.7 (IQR 3.5, 11.4) years. The primary reason for participants not enrolling in the prospective cohort was failure to keep scheduled appointments. There are no significant differences between those included and excluded from the analysis cohort with respect to age, sex, mean hemoglobin level, reticulocyte count, serum creatinine, vaso-occlusive pain rate, or mortality rate, Supporting Information Table S1 . However, individuals included in the prospective cohort had a longer median follow-up time (8.7 vs 1.5 years; P ≤ .001).
Median age of the study cohort at the first visit was 25. 
| DISCUSSION
With improved medical care, children with SCD are now expected to survive into adulthood; however, with improvements in survival, new challenges have started to emerge, including, but not limited to multiple-end-organ disease involving the lungs, heart, and kidneys.
We demonstrate that in a retrospective-prospective cohort of adults with SCD, simultaneous end-organ disease in the lung, heart, and kidney is common, and is associated with earlier mortality.
A unique aspect of the clinical care in our SCD Center of Excellence is the adoption of the Chronic Care Model. 23, 24 In this model of Approximately a quarter of individuals in our cohort had multiple end-organ disease. An increase in the number of organs affected was associated with an increase in the mortality rate. Over 77% of deaths in this adult SCD cohort were related to end-organ impairment as the primary or contributory cause of death. The findings in our cohort are similar to a cohort of 1,056 individuals with SCA followed for 4 decades (starting in 1959), in which 73% of deaths occurred in individuals with one or more clinically recognized forms of SCDrelated irreversible organ damage. 8 Despite the lack of therapy options to prevent progression of lung, heart and kidney disese in SCD, given such a high prevalence and incidence of end-organ disease directly related to early mortality, these data strongly support that surveillance of lung, heart and kidney should be routinely performed. When to start screening for end-organ damage, the best interval for screening, and the optimal management strategy after detection of end-organ disease remain to be established. At the very least, individuals with progressive end-organ disease can be referred to a specialist in these domains for ongoing surveillance, standard therapies used in the general population for specific chronic organ dysfunction or novel therapeutic trials. Despite the lack of specific therapies to stop progression of lung, heart and kidney disease, our group has demonstrated for adults with SCD and ESRD, those receiving pre-dialysis care from a nephrologist, had a lower death rate than those with SCD-ESRD who did not receive medical care from nephrologist pre-dialysis (HR = 0·67, 95% CI 0·45-0·99). 29 These data support the use of comprehensive and speciality medical care for adults with SCD without specific therapy. Although, the currently available evidence does not definitely establish that hydroxyurea therapy prevents progression of end-organ damage, its established effect on reducing mortality warrants its use in most individuals with SCD.
27,28
Hydroxyurea was not a significant predictor of improved survival in our cohort; however, our finding may be due to small numbers in the cohort. Only 42.0% of our cohort were receiving hydroxyurea therapy at the recommended dose of 15-35 mg/kg/day and only 27% had received therapeutically dosed hydroxyurea therapy for 2 or more years cumulatively.
A unique finding in our cohort is that depression (assessed by PHQ-9 scores) is an independent risk factor for earlier death (after adjustment for end-organ disease). Others have shown rates of depression in adults with SCD to range between 18% and 44%, [30] [31] [32] FIGURE 1 Survival for individuals with SCD with and without multiple organ impairment. Multiple organ impairment is defined as involvement of 2 or more organs including the lung (reduced FEV 1 % predicted), heart (elevated TRJV), and kidney (serum creatinine or proteinuria). Time zero was set as time of enrollment in the cohort (baseline) or time of developing multiple vasculopathy. Time to death was 7.8 vs 14.0 years for adults with and without multiple end-organ impairment (log rank P < .001). The effect of multiple end-organ impairment remains significant even after adjusting for age at enrollment, sex, sickle cell phenotype (sickle cell anemia vs other), and hydroxyurea therapy and demonstrated that depression is associated with poorer quality of life. 30, 32 The lower rates of depression in our cohort compared with others may be due to several reasons including the use of a different screening tool and requiring at least 2 assessments at least 4 weeks apart to determine persistent depressive symptoms. The association of depressive symptoms with mortality in SCD is provocative; however, given the small sample size, incomplete concordance between the time of completing PHQ-9 surveys and onset of organ impairment, these results should be considered exploratory. Previous studies in the general population, as well as disease specific populations, have linked depression with mortality. 29, 33, 34 Several mechanisms underlying this association have been proposed, which include cytokine mediated responses, endothelial dysfunction and effects on cardiovascular health. 29, [36] [37] [38] These effects may also be significant in SCD, which is a pro-inflammatory state.
The pathobiology of end-organ impairment in SCD is complex and involves multiple overlapping mechanisms, collectively termed erythrocyte decay-associated molecular patterns. 28 These include disruption of the arginine-nitric oxide pathway, [39] [40] [41] heme-induced oxidative damage, activation of toll-like receptor 4 and inflammasome pathways. [42] [43] [44] Despite an abundance of clinical and basic research on SCD complications, a unified mechanism that explains multiple organ vasculopathy remains elusive, and management of chronic organ complications due to progressive vasculopathy remains a challenge. Several approaches have been tested including sildenafil, 45, 46 bosentan, 47 arginine, 48 and nitric oxide donors 49 for SCD-associated pulmonary hypertension, and angiotensin converting enzyme inhibitors for proteinuria and nephropathy, [50] [51] [52] but none have shown unequivocal benefit in a randomized controlled trial. Pharmacologic disease-modifying therapies preventing the morbidity and mortality associated with irreversible end-organ disease have not been identified [53] [54] [55] ; however, hematopoietic stem cell transplantation has emerged as a curative therapy for SCD, and limited data indicate whether hematopietic tranplant attenuates the progression of end organ impairment. Our study has limitations as expected in an retrospective-prospective cohort. This is not a cohort established in the newborn period and we elected to include only individuals that were at least 18 years of age at end of follow-up. As with other longitudinal epidemiologic studies that enroll patients at different ages, left truncation bias may occur, with organ disease (lung, heart, or kidney) occurring prior to enrollment. 56 Left truncation could also potentially affect the time of multi-organ disease, but no participant was enrolled with multi-organ disease, minimizing this potential bias. There may have been left censoring bias of the key outcome (death), occurring before enrollment.
55
However, we expect over 98% of the children with SCD in highincome countries to reach adulthood. 2, 3 As a result, our study has likely overestimated the age of onset of organ impairment in a proportion of individuals because we did not start screening for end-organ impairment at birth. Our over estimate of the age onset of organ impairment. suggested by previous data, which show that approximately 10% of children and adolescents with SCD (<18 years) have a FEV 1 % predicted ≤70% 48 or TRJV ≥2.5 m/second. 57 As this cohort was not uniformly treated with hydroxyurea therapy for long durations, we cannot determine whether hydroxyurea lowers the incidence of end-organ disease or mortality. Finally, we did not include SCD-related cerebrovascular involvement in the primary analyses because of low compliance rates with CNS imaging and the difficulties in standardizing interpretation of brain MRI in patients with SCD. 21 The results of our single center study need to be validated in other had full access to all of the data in this study and had final responsibility for the decision to submit for publication.
CONFLICT OF INTEREST

